Overview
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204
Description
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study
Eligibility
Inclusion Criteria:
- Type 2 Diabetes Mellitus
Exclusion Criteria:
- Type 1 Diabetes Mellitus
- The subject not meet the specified HbA1c and FPG